

At Psychedelic Science 2017, Amanda Feilding and David Nutt will present their breakthrough LSD and psilocybin findings, and discuss the opportunities and challenges ahead. Rick Doblin and Stanislav Grof will discuss the exciting future of psychedelic-assisted therapy. Roland Griffiths will give an overview of the much-praised Johns Hopkins psilocybin research project, and Anthony P. Bossis will report on NYU's clinical trial on the effects of psilocybin in religious leaders. James Fadiman will share the preliminary results from the world's first survey of psychedelic microdosing.

Psychedelic Science 2017 includes an entire track of presentations on ayahuasca, ibogaine, and other plant medicines, including ground-breaking research on the effects of ayahuasca on neurogenesis, psychiatric distress and depression, as well as on the legal, regulatory, scientific, and ethical issues surrounding ayahuasca churches in the U.S. and internationally. At a time when many countries are facing an escalating opioid epidemic, Psychedelic Science 2017 will feature highly relevant research into substances such as ibogaine and kratom, as treatments for opioid dependence and cannabis as a substitute for opiate-based pain medication.

With over 175 speakers, three full days of workshops, an extensive art gallery and exhibitor marketplace, scientific poster sessions, a Psychedelic Comedy Banquet, and a Sunset Cruise on the San Francisco Bay hosted by The Beckley Foundation, Psychedelic Science 2017 will be an unforgettable celebration of what has been achieved so far, and a comprehensive look at what lies ahead.

CONTACT:

Sasha Frost, The Beckley Foundation (UK)
sasha@beckleyfoundation.org
+44 1865 351209

Brad Burge, MAPS (US)
brad@maps.org
+1 650 863-6887

Media passes: media@maps.org

More information at psychedelicsscience.org.